ATE414539T1 - Verfahren und materialien zur behandlung und diagnose von mit kallikrein-6 zusammenhängenden entzündlichen zuständen - Google Patents
Verfahren und materialien zur behandlung und diagnose von mit kallikrein-6 zusammenhängenden entzündlichen zuständenInfo
- Publication number
- ATE414539T1 ATE414539T1 AT03734121T AT03734121T ATE414539T1 AT E414539 T1 ATE414539 T1 AT E414539T1 AT 03734121 T AT03734121 T AT 03734121T AT 03734121 T AT03734121 T AT 03734121T AT E414539 T1 ATE414539 T1 AT E414539T1
- Authority
- AT
- Austria
- Prior art keywords
- methods
- kallikrein
- inflammatory conditions
- diagnosis
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96433—Serine endopeptidases (3.4.21)
- G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
- G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/104—Lupus erythematosus [SLE]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/285—Demyelinating diseases; Multipel sclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Rheumatology (AREA)
- Rehabilitation Therapy (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38247102P | 2002-05-21 | 2002-05-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE414539T1 true ATE414539T1 (de) | 2008-12-15 |
Family
ID=29584413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03734121T ATE414539T1 (de) | 2002-05-21 | 2003-05-21 | Verfahren und materialien zur behandlung und diagnose von mit kallikrein-6 zusammenhängenden entzündlichen zuständen |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US7754216B2 (de) |
| EP (2) | EP2189166A1 (de) |
| AT (1) | ATE414539T1 (de) |
| AU (1) | AU2003239558A1 (de) |
| CA (1) | CA2486619A1 (de) |
| DE (1) | DE60324796D1 (de) |
| ES (1) | ES2316770T3 (de) |
| WO (1) | WO2003099328A1 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4135019B2 (ja) * | 2006-04-28 | 2008-08-20 | 住友電気工業株式会社 | 半導体レーザ |
| US8530427B2 (en) * | 2010-09-30 | 2013-09-10 | Mayo Foundation For Medical Education And Research | Methods for modulating resistance to apoptosis using KLK6 |
| WO2014019644A1 (en) * | 2012-07-31 | 2014-02-06 | Baxter International Inc. | Selective measurement of active human protease coagulation factors |
| US9783587B1 (en) | 2014-05-09 | 2017-10-10 | Florida State University Research Foundation | Synthetic foldable proteins generated from peptide segments of folding nuclei of reference proteins |
| US20160213633A1 (en) * | 2015-01-28 | 2016-07-28 | Teva Pharmaceutical Industries, Ltd. | Method of inducing anti-glatiramer acetate antibody response |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3687808A (en) * | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
| US4034074A (en) * | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US4098876A (en) * | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4233402A (en) * | 1978-04-05 | 1980-11-11 | Syva Company | Reagents and method employing channeling |
| US4469863A (en) * | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
| US5235033A (en) * | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
| US5444156A (en) * | 1985-07-12 | 1995-08-22 | Temple University-Of The Commonwealth System Of Higher Education | Monoclonal antibodies to human plasma prekallikrein |
| US5750666A (en) * | 1988-05-26 | 1998-05-12 | Competitve Technologies, Inc. | Polynucleotide phosphorodithioate compounds |
| US5214136A (en) * | 1990-02-20 | 1993-05-25 | Gilead Sciences, Inc. | Anthraquinone-derivatives oligonucleotides |
| US5218105A (en) * | 1990-07-27 | 1993-06-08 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
| JPH06505704A (ja) * | 1990-09-20 | 1994-06-30 | ギリアド サイエンシズ,インコーポレイテッド | 改変ヌクレオシド間結合 |
| US5296347A (en) * | 1991-02-08 | 1994-03-22 | Ciba Corning Diagnostics Corp. | Bridge immunoassay |
| SE9301916D0 (sv) * | 1993-06-03 | 1993-06-03 | Ab Astra | New peptides derivatives |
| AU4480797A (en) * | 1996-09-13 | 1998-04-02 | Dana-Farber Cancer Institute | Protease m, a novel serine protease |
| US6319906B1 (en) | 1996-12-31 | 2001-11-20 | Isis Pharmaceuticals | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein |
| WO2000001807A1 (en) * | 1998-07-02 | 2000-01-13 | Fuso Pharmaceutical Industries, Ltd. | Serine protease-specific monoclonal antibody and utilization thereof |
| CA2360219A1 (en) | 2000-10-27 | 2002-04-27 | Mount Sinai Hospital | Method for detecting alzheimer's disease |
-
2003
- 2003-05-21 WO PCT/US2003/016106 patent/WO2003099328A1/en not_active Ceased
- 2003-05-21 EP EP08019970A patent/EP2189166A1/de not_active Withdrawn
- 2003-05-21 DE DE60324796T patent/DE60324796D1/de not_active Expired - Lifetime
- 2003-05-21 EP EP03734121A patent/EP1513553B1/de not_active Expired - Lifetime
- 2003-05-21 US US10/514,687 patent/US7754216B2/en active Active
- 2003-05-21 AU AU2003239558A patent/AU2003239558A1/en not_active Abandoned
- 2003-05-21 CA CA002486619A patent/CA2486619A1/en not_active Abandoned
- 2003-05-21 ES ES03734121T patent/ES2316770T3/es not_active Expired - Lifetime
- 2003-05-21 AT AT03734121T patent/ATE414539T1/de not_active IP Right Cessation
-
2010
- 2010-07-09 US US12/833,773 patent/US20110008789A1/en not_active Abandoned
-
2013
- 2013-05-23 US US13/901,409 patent/US20130323262A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003239558A1 (en) | 2003-12-12 |
| US20060127391A1 (en) | 2006-06-15 |
| ES2316770T3 (es) | 2009-04-16 |
| EP2189166A1 (de) | 2010-05-26 |
| US20130323262A1 (en) | 2013-12-05 |
| CA2486619A1 (en) | 2003-12-04 |
| EP1513553A1 (de) | 2005-03-16 |
| US20110008789A1 (en) | 2011-01-13 |
| WO2003099328A1 (en) | 2003-12-04 |
| US7754216B2 (en) | 2010-07-13 |
| EP1513553B1 (de) | 2008-11-19 |
| EP1513553A4 (de) | 2006-03-22 |
| DE60324796D1 (de) | 2009-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE516042T1 (de) | Zusammensetzungen und verfahren zur behandlung und diagnose von tumoren | |
| ATE493433T1 (de) | Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen | |
| ATE522623T1 (de) | Zusammensetzungen und verfahren zur behandlung und diagnose von lungentumoren | |
| DE60331892D1 (de) | Operationsinstrument und Verfahren zur Behandlung von Organvorfall | |
| DE60311820D1 (de) | Neue verwendung von pyrimidin- oder triazin-2-carbonsäurenitrilen zur behandlung von krankheiten, die mit cysteinproteaseaktivität assoziiert sind, und neue pyridimidin-2-carbonsäurenitrilderivate | |
| DE122009000075I1 (de) | Methoden und zusammensetzungen für die behandlung von glomerulonephritis | |
| ATE331527T1 (de) | Verfahren zur behandlung von brustdrüsenerkrankungen | |
| DE60335293D1 (de) | Pyrrolopyridazin-verbindungen und verwendungsverfahren dafür zur behandlung von proliferativen erkrankungen | |
| EP1701664A4 (de) | System und verfahren zur behandlung von gewebe | |
| ATE554756T1 (de) | Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen | |
| EP1550462A4 (de) | MITTEL ZUR BEHANDLUNG ODER PRûVENTION VON NIERENERKRANKUNGEN UND VERFAHREN ZUR DIAGNOSE VON NIERENERKRANKUNGEN | |
| EP1117395A4 (de) | Verbindungen zur behandlung von östrogenabhängigen erkrankungen und deren herstellungs und verwendungsmethoden | |
| DE602004023721D1 (de) | Zusammensetzungen und methoden für die behandlung von herzerkrankungen | |
| ATE423110T1 (de) | Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen | |
| EP1812588A4 (de) | Anomalitäten von phosphatase 2a (pp2a) zur diagnose und behandlung von morbus alzheimer | |
| ATE494296T1 (de) | Zusammensetzungen und verfahren für die tumordiagnose und behandlung | |
| DE60218153D1 (de) | Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges | |
| ATE338142T1 (de) | Methoden zur diagnose und behandlung von herzkrankheiten | |
| ATE414539T1 (de) | Verfahren und materialien zur behandlung und diagnose von mit kallikrein-6 zusammenhängenden entzündlichen zuständen | |
| DE60313803D1 (de) | Cathepsincysteinproteaseinhibitoren und deren verwendung zur behandlung von entzündungen und immunerkrankungen | |
| EP4446407A4 (de) | Manipulierter mikroorganismus zur behandlung von hyperphenylalaninämie und verwendung davon | |
| DE602006009786D1 (de) | Anwendung von molekülen und verfahren zur behandlung von mit mcp-1/ccr2 assoziierten krankheiten | |
| ATE521631T1 (de) | Verwendung von aimp2dx2 zur diagnose und behandlung von krebs | |
| DE59813914D1 (de) | Mittel zur behandlung und/oder prophylaxe von mikrozirkulationsstörungen | |
| ATE473277T1 (de) | Zusammensetzungen und verfahren zur prävention und behandlung von immunvermittelten entzündungskrankheiten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |